Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||0.02 x 100|
|Ask||250.06 x 100|
|Day's Range||116.61 - 119.60|
|52 Week Range||96.52 - 192.94|
|PE Ratio (TTM)||-11.96|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.